<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="213">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05158374</url>
  </required_header>
  <id_info>
    <org_study_id>AC21120</org_study_id>
    <nct_id>NCT05158374</nct_id>
  </id_info>
  <brief_title>Molecular Effects of Aspirin &amp; Metformin on Colonic Epithelium</brief_title>
  <official_title>Molecular Effects of Aspirin &amp; Metformin on Colonic Epithelium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bowel cancer, a significant problem in the United Kingdom (UK) with ~ 41,000 diagnoses and ~&#xD;
      16,000 deaths annually, has a large preventable component (~54%). It is, in part, due to&#xD;
      energy imbalance within bowel cells as suggested by associated risk factors: high-fat diet,&#xD;
      obesity, physical inactivity and type 2 diabetes mellitus. Drugs that decrease bowel cancer&#xD;
      risk, like aspirin and metformin, may prevent the disease by mimicking the molecular effects&#xD;
      of dietary restriction and exercise.&#xD;
&#xD;
      Energy imbalance, through obesity, expands stem cells which may increase bowel cancer. We&#xD;
      have shown that aspirin activates an energy molecule, which increases when we exercise, and&#xD;
      blocks signalling associated with obesity in bowel cancer. Indeed aspirin in combination with&#xD;
      metformin (commonly used in diabetes) has a greater effect on this pathway than either drug&#xD;
      alone.&#xD;
&#xD;
      To predict which patients may benefit from aspirin and metformin, we need to discover if&#xD;
      these drugs may mimic healthy lifestyle changes at a cellular level and which cells are being&#xD;
      targeted.&#xD;
&#xD;
      This project investigates how aspirin and metformin influence energy molecules in bowel cells&#xD;
      to mimic beneficial effects of exercise or dietary restriction. Participants, recruited from&#xD;
      Western General Hospital (Edinburgh) colorectal clinics, will have bowel lining and blood&#xD;
      samples take initially and then depending on their assigned cohort, after; 24 hours, 7 days,&#xD;
      28 days or a 6-week course of aspirin, metformin or both tablets. Samples will be analysed&#xD;
      for energy genes (main outcome). Secondary outcomes will measure effects on quantitative&#xD;
      faecal immunochemical tests (qFIT), used to detect blood in the stool, and on gut bacteria.&#xD;
&#xD;
      This critical research will inform how aspirin and metformin can be used in specific&#xD;
      populations to decrease bowel cancer risk and to develop new drugs to target abnormal energy&#xD;
      pathways.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Colorectal cancer (CRC) is eminently preventable, and yet it is the 2nd most common cause of&#xD;
      cancer death in the UK. Both population growth and ageing will influence CRC incidence. There&#xD;
      is a significant environmental aetiological component, with around 54% being preventable.&#xD;
      Modifiable risk factors include obesity, metabolic syndrome, type 2 diabetes mellitus (T2DM),&#xD;
      and physical inactivity.Recent data suggests that the rising CRC incidence in young&#xD;
      populations is associated with the increase in obesity and T2DM. Hence, there is substantial&#xD;
      rationale for developing approaches that define and modify CRC obesity-related risk. Cancer&#xD;
      cells have long been observed to reprogramme metabolism to generate substrates for growth.&#xD;
      There are multiple molecular mechanisms linking obesity and CRC. Obesity is the commonest&#xD;
      cause of insulin resistance and T2DM. Obesity-mediated insulin resistance and inflammation&#xD;
      may drive CRC. Obesity increases early CRC precursor lesions of aberrant crypt foci.&#xD;
      Bariatric surgery reduces adenomas and decreases CRC risk biomarkers such as proliferation&#xD;
      and inflammation markers. High-fat diet (HFD) animal models of obesity and carcinogen-induced&#xD;
      CRC show intestinal stem cell expansion. Dietary fatty acids themselves may drive stem cell&#xD;
      expansion. Highlighting further complexity, intestinal epithelial insulin receptor deletion&#xD;
      attenuates the HFD-induced increase in cholesterol and stem cell messenger ribonucleic acids&#xD;
      (mRNAs).&#xD;
&#xD;
      Calorie restriction, associated with longevity and reduced cancer incidence, may be mediated&#xD;
      through downregulation of nutrient-sensing pathways. Agents that clearly decrease CRC&#xD;
      incidence, such as aspirin and metformin (may act as calorie restriction mimetics by&#xD;
      influencing nutrient-sensing. The host lab have shown that low-dose aspirin reduces CRC&#xD;
      incidence in the Scottish population and that high-energy snacks are associated with CRC risk&#xD;
      -strengthening the link between energy, diet and cancer. They also demonstrated that aspirin&#xD;
      modulates key nutrient-sensing pathways; aspirin activates AMP-activated protein kinase&#xD;
      (AMPK) and inhibits mammalian target of rapamycin (mTOR) signalling in CRC cells, mouse&#xD;
      intestine and patients. Furthermore, there was a synergistic effect with aspirin and&#xD;
      metformin with respect to AMPK activation and mTOR inhibition in CRC cells. The protective&#xD;
      effect of aspirin may be greater in higher body-mass index (BMI) patients. Mendelian&#xD;
      randomisation studies strengthen causal links between obesity, hyperlipidaemia,&#xD;
      pro-inflammatory fatty acids and CRC risk.&#xD;
&#xD;
      This study aims to elucidate the underlying molecular mechanisms of aspirin and metformin&#xD;
      with respect to their cancer preventing properties in the colon, thereby identifying&#xD;
      potential critical &quot;druggable&quot; targets. The ultimate aim is to predict which patients may&#xD;
      benefit from these drugs to prevent CRC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2022</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative genetic expression change of genes relating to energy, metabolism and stem cell signalling in the large bowel</measure>
    <time_frame>Baseline and immediately after 24 hours Aspirin medication</time_frame>
    <description>Effect on genetic expression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative genetic expression change of genes relating to energy, metabolism and stem cell signalling in the large bowel</measure>
    <time_frame>Baseline and immediately after 7 days Aspirin medication</time_frame>
    <description>Effect on genetic expression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative genetic expression change of genes relating to energy, metabolism and stem cell signalling in the large bowel</measure>
    <time_frame>Baseline and immediately after 28 days Aspirin medication</time_frame>
    <description>Effect on genetic expression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative genetic expression change of genes relating to energy, metabolism and stem cell signalling in the large bowel</measure>
    <time_frame>Baseline and immediately after 6 weeks Aspirin medication</time_frame>
    <description>Effect on genetic expression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative genetic expression change of genes relating to energy, metabolism and stem cell signalling in the large bowel</measure>
    <time_frame>Baseline and immediately after 24 hours Metformin medication</time_frame>
    <description>Effect on genetic expression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative genetic expression change of genes relating to energy, metabolism and stem cell signalling in the large bowel</measure>
    <time_frame>Baseline and immediately after 7 days Metformin medication</time_frame>
    <description>Effect on genetic expression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative genetic expression change of genes relating to energy, metabolism and stem cell signalling in the large bowel</measure>
    <time_frame>Baseline and immediately after 28 days Metformin medication</time_frame>
    <description>Effect on genetic expression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative genetic expression change of genes relating to energy, metabolism and stem cell signalling in the large bowel</measure>
    <time_frame>Baseline and immediately after 6 weeks Metformin medication</time_frame>
    <description>Effect on genetic expression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative genetic expression change of genes relating to energy, metabolism and stem cell signalling in the large bowel</measure>
    <time_frame>Baseline and immediately after 24 hours combined Aspirin and Metformin medication</time_frame>
    <description>Effect on genetic expression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative genetic expression change of genes relating to energy, metabolism and stem cell signalling in the large bowel</measure>
    <time_frame>Baseline and immediately after 7 days combined Aspirin and Metformin medication</time_frame>
    <description>Effect on genetic expression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative genetic expression change of genes relating to energy, metabolism and stem cell signalling in the large bowel</measure>
    <time_frame>Baseline and immediately after 28 days combined Aspirin and Metformin medication</time_frame>
    <description>Effect on genetic expression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative genetic expression change of genes relating to energy, metabolism and stem cell signalling in the large bowel</measure>
    <time_frame>Baseline and immediately after 6 weeks combined Aspirin and Metformin medication</time_frame>
    <description>Effect on genetic expression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in value of qFIT result with aspirin, metformin or combination</measure>
    <time_frame>Baseline and immediately after 24 hours Aspirin medication</time_frame>
    <description>Effect of qFIT value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in value of qFIT result with aspirin, metformin or combination</measure>
    <time_frame>Baseline and immediately after 7 days Aspirin medication</time_frame>
    <description>Effect of qFIT value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in value of qFIT result with aspirin, metformin or combination</measure>
    <time_frame>Baseline and immediately after 28 days Aspirin medication</time_frame>
    <description>Effect of qFIT value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in value of qFIT result with aspirin, metformin or combination</measure>
    <time_frame>Baseline and immediately after 6 weeks Aspirin medication</time_frame>
    <description>Effect of qFIT value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in value of qFIT result with aspirin, metformin or combination</measure>
    <time_frame>Baseline and immediately after 24 hours Metformin medication</time_frame>
    <description>Effect of qFIT value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in value of qFIT result with aspirin, metformin or combination</measure>
    <time_frame>Baseline and immediately after 7 days Metformin medication</time_frame>
    <description>Effect of qFIT value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in value of qFIT result with aspirin, metformin or combination</measure>
    <time_frame>Baseline and immediately after 28 days Metformin medication</time_frame>
    <description>Effect of qFIT value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in value of qFIT result with aspirin, metformin or combination</measure>
    <time_frame>Baseline and immediately after 6 weeks Metformin medication</time_frame>
    <description>Effect of qFIT value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in value of qFIT result with aspirin, metformin or combination</measure>
    <time_frame>Baseline and immediately after 24 hours Aspirin and Metformin medication</time_frame>
    <description>Effect of qFIT value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in value of qFIT result with aspirin, metformin or combination</measure>
    <time_frame>Baseline and immediately after 7 days Aspirin and Metformin medication</time_frame>
    <description>Effect of qFIT value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in value of qFIT result with aspirin, metformin or combination</measure>
    <time_frame>Baseline and immediately after 28 days Aspirin and Metformin medication</time_frame>
    <description>Effect of qFIT value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in value of qFIT result with aspirin, metformin or combination</measure>
    <time_frame>Baseline and immediately after 6 weeks Aspirin and Metformin medication</time_frame>
    <description>Effect of qFIT value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alterations if the colorectal microbiome after aspirin and/or metformin medication</measure>
    <time_frame>Baseline and immediately after 24 hours Aspirin medication</time_frame>
    <description>Effect on microbiome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alterations if the colorectal microbiome after aspirin and/or metformin medication</measure>
    <time_frame>Baseline and immediately after 7 days Aspirin medication</time_frame>
    <description>Effect on microbiome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alterations if the colorectal microbiome after aspirin and/or metformin medication</measure>
    <time_frame>Baseline and immediately after 28 days Aspirin medication</time_frame>
    <description>Effect on microbiome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alterations if the colorectal microbiome after aspirin and/or metformin medication</measure>
    <time_frame>Baseline and immediately after 6 weeks Aspirin medication</time_frame>
    <description>Effect on microbiome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alterations if the colorectal microbiome after aspirin and/or metformin medication</measure>
    <time_frame>Baseline and immediately after 24 hours Metformin medication</time_frame>
    <description>Effect on microbiome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alterations if the colorectal microbiome after aspirin and/or metformin medication</measure>
    <time_frame>Baseline and immediately after 7 days Metformin medication</time_frame>
    <description>Effect on microbiome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alterations if the colorectal microbiome after aspirin and/or metformin medication</measure>
    <time_frame>Baseline and immediately after 28 days Metformin medication</time_frame>
    <description>Effect on microbiome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alterations if the colorectal microbiome after aspirin and/or metformin medication</measure>
    <time_frame>Baseline and immediately after 6 weeks Metformin medication</time_frame>
    <description>Effect on microbiome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alterations if the colorectal microbiome after aspirin and/or metformin medication</measure>
    <time_frame>Baseline and immediately after 24 hours Aspirin and Metformin medication</time_frame>
    <description>Effect on microbiome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alterations if the colorectal microbiome after aspirin and/or metformin medication</measure>
    <time_frame>Baseline and immediately after 7 days Aspirin and Metformin medication</time_frame>
    <description>Effect on microbiome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alterations if the colorectal microbiome after aspirin and/or metformin medication</measure>
    <time_frame>Baseline and immediately after 28 days Aspirin and Metformin medication</time_frame>
    <description>Effect on microbiome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alterations if the colorectal microbiome after aspirin and/or metformin medication</measure>
    <time_frame>Baseline and immediately after 6 weeks Aspirin and Metformin medication</time_frame>
    <description>Effect on microbiome</description>
  </secondary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Colorectal Neoplasms</condition>
  <condition>Colorectal Adenoma</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No medication, 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin 24 Hours</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>24 Hours Aspirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin 7 Days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7 Days Aspirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin 28 Days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>28 Days Aspirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin 6 Weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 Weeks Aspirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin 24 Hours</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>24 Hours Metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin 7 Days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7 Days Metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin 28 Days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>28 Days Metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin 6 Weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 Weeks Metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin &amp; Metformin 24 Hours</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>24 Hours Aspirin &amp; Metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin &amp; Metformin 7 Days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7 Days Aspirin &amp; Metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin &amp; Metformin 28 Days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>28 Days Aspirin &amp; Metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin &amp; Metformin 6 Weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 Weeks Aspirin &amp; Metformin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin tablet</intervention_name>
    <description>75mg Aspirin once per day</description>
    <arm_group_label>Aspirin 24 Hours</arm_group_label>
    <arm_group_label>Aspirin 28 Days</arm_group_label>
    <arm_group_label>Aspirin 6 Weeks</arm_group_label>
    <arm_group_label>Aspirin 7 Days</arm_group_label>
    <other_name>acetylsalicylic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>500mg Metformin once per day</description>
    <arm_group_label>Metformin 24 Hours</arm_group_label>
    <arm_group_label>Metformin 28 Days</arm_group_label>
    <arm_group_label>Metformin 6 Weeks</arm_group_label>
    <arm_group_label>Metformin 7 Days</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin and Metformin</intervention_name>
    <description>75mg Aspirin and 500mg Metformin once per day</description>
    <arm_group_label>Aspirin &amp; Metformin 24 Hours</arm_group_label>
    <arm_group_label>Aspirin &amp; Metformin 28 Days</arm_group_label>
    <arm_group_label>Aspirin &amp; Metformin 6 Weeks</arm_group_label>
    <arm_group_label>Aspirin &amp; Metformin 7 Days</arm_group_label>
    <other_name>acetylsalicylic acid and Glucophage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All participants who are capable of giving informed consent. All participants aged 16 years&#xD;
        or over. All participants must have no known contraindications to rectal biopsy procedures.&#xD;
&#xD;
        All participants must be resident in the United Kingdom. All participants must have no&#xD;
        known contraindications to aspirin and metformin.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Unable to give informed consent. Under the age of 16 years. Individuals who are taking&#xD;
        anti-coagulation medication. Individuals with platelet disease or other bleeding issues.&#xD;
        Individuals with a history of a significant rectal bleed. History of diabetes mellitus or&#xD;
        impaired glucose tolerance. Any contraindication to either aspirin or metformin. Female&#xD;
        subjects of child bearing age who are not taking effective contraception during the period&#xD;
        of the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Farhat VN Din, FRCSed</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Edinburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Farhat VN Din, FRCSed</last_name>
    <phone>01315371423</phone>
    <email>Farhat.Din@ed.ac.uk</email>
  </overall_contact>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 17, 2021</study_first_submitted>
  <study_first_submitted_qc>December 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2021</study_first_posted>
  <last_update_submitted>December 1, 2021</last_update_submitted>
  <last_update_submitted_qc>December 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Adenoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

